Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia
- Conditions
- Herpes Zoster
- Interventions
- Diagnostic Test: Hospital Anxiety and Depression Scale
- Registration Number
- NCT06449547
- Lead Sponsor
- Huazhong University of Science and Technology
- Brief Summary
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.
- Detailed Description
Patients with herpes zoster neuralgia will be recruited and take Hospital anxiety depression rating scale (Hospital anxiety and 'scale, HADS) evaluation. According to the HADS Scores, patients will be divided into depression group and no depression, or anxiety group and no anxiety group. The clinical data the of two groups will be collected and statistically analyzed to explore the risk factors of anxiety and depression, including the changes of serum biomarkers and functional brain magnetic resonance imaging in patients with herpes zoster neuralgia accompanying anxiety or depression.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 600
- Age more than 18 years old
- Diagnosed as herpes zoster neuralgia
- Signing informed consent
- Unable to complete the scale assessment
- History of mental illness
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description patients with depression Hospital Anxiety and Depression Scale Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Depression questionnaire. patients without anxiety Hospital Anxiety and Depression Scale Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire. patients with anxiety Hospital Anxiety and Depression Scale Patients in this group suffered from herpes zoster neuralgia and had a score more than or equal to 8 for Hospital Anxiety and Depression Scale- Anxiety questionnaire. patients without depression Hospital Anxiety and Depression Scale Patients in this group suffered from herpes zoster neuralgia and had a score less than 8 for Hospital Anxiety and Depression Scale- Depression questionnaire.
- Primary Outcome Measures
Name Time Method HADS score during hospital stay, average of 1 week Enrolled patients will be first evaluated by Hospital Anxiety and Depression Scare questionaire and according to the HADS score, patients will be divided to group with anxiety/depression and group without anxiety/depression.
- Secondary Outcome Measures
Name Time Method IL-6 plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-6 （pg/ml）will be tested.
Interleukin (IL）-1β plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-1β （pg/ml）will be tested.
C-reactive protein (CRP) plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of CRP（mg/ml）will be tested.
Area under curve (AUC) of topological metrics of functional brain magnetic resonance imaging during hospital stay, average of 1 week Functional brain magnetic resonance imaging will be performed in patients with anxiety or depression, and area under curve (AUC) of topological metrics including Eglob,Eloc,Cp,Lp,γ,λ and σ will be calculated and analyzed.
IL-2 receptor plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-2 （u/ml）will be tested.
IL-10 plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-10 （pg/ml）will be tested.
Interferon(INF)-α plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines INF-α （pg/ml）will be tested.
IL-8 plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-8 （pg/ml）will be tested.
Brain-derived neurotrophic factor (BDNF) plasma level during hospital stay, average of 1 week Blood sample will be obtained from enrolled patients and the plasma level of BDNF（pg/ml）will be tested.
Trial Locations
- Locations (1)
Tongji hospital
🇨🇳Wuhan, Hubei, China